JP2012523395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523395A5 JP2012523395A5 JP2012504028A JP2012504028A JP2012523395A5 JP 2012523395 A5 JP2012523395 A5 JP 2012523395A5 JP 2012504028 A JP2012504028 A JP 2012504028A JP 2012504028 A JP2012504028 A JP 2012504028A JP 2012523395 A5 JP2012523395 A5 JP 2012523395A5
- Authority
- JP
- Japan
- Prior art keywords
- saxagliptin hydrochloride
- crystalline
- saxagliptin
- degrees
- peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TUAZNHHHYVBVBR-NHKADLRUSA-N (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 TUAZNHHHYVBVBR-NHKADLRUSA-N 0.000 claims description 16
- 229960004973 saxagliptin hydrochloride Drugs 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 238000002329 infrared spectrum Methods 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229960004937 saxagliptin Drugs 0.000 claims 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 1
- 108010033693 saxagliptin Proteins 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16791809P | 2009-04-09 | 2009-04-09 | |
| EP09157723.9 | 2009-04-09 | ||
| US61/167,918 | 2009-04-09 | ||
| EP09157723 | 2009-04-09 | ||
| EP09175259 | 2009-11-06 | ||
| EP09175259.2 | 2009-11-06 | ||
| PCT/EP2010/054692 WO2010115974A1 (en) | 2009-04-09 | 2010-04-09 | Crystal forms of saxagliptin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015141890A Division JP2016006063A (ja) | 2009-04-09 | 2015-07-16 | サクサグリプチンの結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012523395A JP2012523395A (ja) | 2012-10-04 |
| JP2012523395A5 true JP2012523395A5 (enExample) | 2014-11-06 |
| JP6088245B2 JP6088245B2 (ja) | 2017-03-01 |
Family
ID=42935672
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012504028A Expired - Fee Related JP6088245B2 (ja) | 2009-04-09 | 2010-04-09 | サクサグリプチンの結晶形態 |
| JP2015141890A Pending JP2016006063A (ja) | 2009-04-09 | 2015-07-16 | サクサグリプチンの結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015141890A Pending JP2016006063A (ja) | 2009-04-09 | 2015-07-16 | サクサグリプチンの結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20120088808A1 (enExample) |
| EP (1) | EP2417107B1 (enExample) |
| JP (2) | JP6088245B2 (enExample) |
| KR (1) | KR20120006047A (enExample) |
| CN (2) | CN102459170B (enExample) |
| AU (1) | AU2010233718B2 (enExample) |
| BR (1) | BRPI1006547A2 (enExample) |
| CA (1) | CA2757934C (enExample) |
| ES (1) | ES2548386T3 (enExample) |
| PL (1) | PL2417107T3 (enExample) |
| RU (1) | RU2539590C2 (enExample) |
| WO (1) | WO2010115974A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0487425A (ja) * | 1990-07-31 | 1992-03-19 | Fujitsu Ltd | 回線切り替え装置 |
| US20120088808A1 (en) * | 2009-04-09 | 2012-04-12 | Sandoz Ag | Crystal forms of saxagliptin |
| CN102686594A (zh) * | 2009-12-16 | 2012-09-19 | 熙德隆研究基金会 | 地瑞那韦的多晶型物 |
| PT2571355T (pt) | 2010-05-20 | 2016-10-17 | Hetero Research Foundation | Sal de cloridrato cristalino de darunavir |
| EP2608788A1 (en) | 2010-10-04 | 2013-07-03 | Assia Chemical Industries Ltd. | Polymorphs of saxagliptin hydrochloride and processes for preparing them |
| EA201490556A1 (ru) | 2011-09-07 | 2014-08-29 | Сановел Илач Санайи Ве Тиджарет Аноним Ширкети | Составы ингибитора дпп-4 |
| PL2578208T3 (pl) | 2011-10-06 | 2014-10-31 | Sanovel Ilac Sanayi Ve Ticaret As | Stałe formulacje dawkowane inhibitora DPP-IV |
| WO2013136343A1 (en) | 2012-03-12 | 2013-09-19 | Mylan Laboratories Ltd. | Amorphous saxagliptin hydrochloride |
| WO2013160354A1 (en) * | 2012-04-25 | 2013-10-31 | Enantia, S.L. | Crystalline forms of saxagliptin |
| WO2013175297A1 (en) | 2012-05-24 | 2013-11-28 | Apotex Pharmachem India Pvt. Ltd | Salts of saxagliptin with organic acids |
| AU2013285078A1 (en) | 2012-07-02 | 2015-01-29 | Sun Pharmaceutical Industries Limited | Saxagliptin salts |
| WO2015067223A1 (en) | 2013-11-06 | 2015-05-14 | Zentiva, K., S. | L-tartrate salt of (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and process for preparation thereof |
| JP2022182181A (ja) * | 2021-05-27 | 2022-12-08 | キョーリンリメディオ株式会社 | ビルダグリプチン含有医薬品 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6032616B2 (ja) * | 1976-08-24 | 1985-07-29 | アレクサンダ− ガラツト | 高い貯蔵安定性の無水アセチルサリチル酸ナトリウム |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US7420079B2 (en) * | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| BRPI0512708A (pt) * | 2004-07-16 | 2008-04-01 | Warner Lambert Co | agentes promotores de crescimento de cabelo |
| US20060035954A1 (en) * | 2004-08-11 | 2006-02-16 | Sharma Padam N | Ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
| PE20090696A1 (es) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
| US20120088808A1 (en) * | 2009-04-09 | 2012-04-12 | Sandoz Ag | Crystal forms of saxagliptin |
-
2010
- 2010-04-09 US US13/262,652 patent/US20120088808A1/en not_active Abandoned
- 2010-04-09 ES ES10713211.0T patent/ES2548386T3/es active Active
- 2010-04-09 EP EP10713211.0A patent/EP2417107B1/en not_active Not-in-force
- 2010-04-09 BR BRPI1006547A patent/BRPI1006547A2/pt not_active Application Discontinuation
- 2010-04-09 CA CA2757934A patent/CA2757934C/en not_active Expired - Fee Related
- 2010-04-09 CN CN201080025360.7A patent/CN102459170B/zh not_active Expired - Fee Related
- 2010-04-09 JP JP2012504028A patent/JP6088245B2/ja not_active Expired - Fee Related
- 2010-04-09 KR KR1020117026595A patent/KR20120006047A/ko not_active Abandoned
- 2010-04-09 RU RU2011145054/04A patent/RU2539590C2/ru not_active IP Right Cessation
- 2010-04-09 AU AU2010233718A patent/AU2010233718B2/en not_active Ceased
- 2010-04-09 WO PCT/EP2010/054692 patent/WO2010115974A1/en not_active Ceased
- 2010-04-09 CN CN201410283458.2A patent/CN104016902B/zh not_active Expired - Fee Related
- 2010-04-09 PL PL10713211T patent/PL2417107T3/pl unknown
-
2013
- 2013-10-02 US US14/044,204 patent/US9260389B2/en active Active
-
2015
- 2015-07-16 JP JP2015141890A patent/JP2016006063A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523395A5 (enExample) | ||
| RU2011145054A (ru) | Кристаллические формы саксаглиптина | |
| RU2462456C2 (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| JP2009537498A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2014518266A5 (enExample) | ||
| CA2765529C (en) | Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility | |
| JP2013534248A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| CN116804007B (zh) | 普瑞利伟游离碱半水合物、其制造方法和用途 | |
| JP2012508215A5 (enExample) | ||
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| JP2012530779A5 (enExample) | ||
| JP2010519300A5 (enExample) | ||
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| JP2009526794A5 (enExample) | ||
| JP2015522589A5 (enExample) | ||
| JP2007507494A5 (enExample) | ||
| EP3404029A3 (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| JP2011046708A5 (enExample) | ||
| CA2530308A1 (en) | 5ht2c receptor agonists for the treatment of diabetes and obesity | |
| CN110225781A (zh) | 噻唑衍生物及其应用 | |
| JP2015522037A5 (enExample) | ||
| JP2016539136A5 (enExample) | ||
| RU2013156069A (ru) | Полиморфная форма 4-{[4-({[4-(2,2,2,-трифторэтокси)-1,2-бензизоксазол-3-ил]окси}метил)пиперидин-1-ил]метил}-тетрагидро-2н-пиран-4-карбоновой кислоты |